Результаты поиска

Development of an Undiagnosed Mass Registry: Lessons Learned From Our First 100 Patients.

IntroductionThe Undiagnosed Mass Clinic (UMC) at our institution is a clinical and research program created to address gaps in the early diagnostic phase of the cancer care continuum for patients with potential malignant neoplasms. All patients referred to the UMC are invited to participate in the UMC registry, which tracks operational and clinical metrics while maintaining a repository of blood and tissue specimens for future research.MethodsWe conducted a retrospective cohort study of the first 100 patients enrolled in the UMC registry. We analyzed patient demographics, final diagnoses, and

Practical management of disease-related manifestations and drug toxicities in patients with multiple myeloma.

Multiple myeloma (MM) is a very heterogeneous disease with multiple symptoms and clinical manifestations. MM affects mainly elderly patients and is difficult to manage in the presence of comorbidities, polypharmacy, frailty and adverse events of disease-targeted drugs. The rapid changes in MM treatment resulting from constant innovations in this area, together with the introduction of numerous new drugs with distinct mechanisms of action and toxicity profiles, have led to an increased complexity in the therapeutic decision-making and patient management processes. The prolonged exposure to nove

Synchronous occurrence of Waldenström macroglobulinemia and HER2-positive gastric adenocarcinoma with gastrointestinal stromal tumor: a rare case report.

There are very few reports of gastric cancer (GC) and gastrointestinal stromal tumor (GIST) occurring at the same time in the literature. In particular, the collision of GIST and human epidermal growth factor receptor-2 (HER-2)-positive gastric carcinoma in a patient with Waldenström macroglobulinemia (WM) has never been reported. We report the case of an 80-year-old male who initially presented with dizziness with fatigue for more than 1 month. He underwent total gastrectomy. Pathology revealed GC (moderately to poorly differentiated tubular adenocarcinoma), GIST (low-risk category) and low-g

Skin manifestations associated with systemic diseases - Part I.

The skin demonstrates what is happening in the body in many diseases, as it reflects some internal processes on the surface. In this sense, skin as an organ, goes beyond its protective and barrier functions, as it provides clues for the identification of some systemic diseases. The dermatologist then raises diagnostic hypotheses for conditions related to all systems and refers them to the appropriate specialty. With easy access to examination by trained eyes and biopsies, the skin can present specific or non specific alterations on histopathology. In the first case this combination establishes

Tumor biomarkers for diagnosis, prognosis and targeted therapy.

Tumor biomarkers, the substances which are produced by tumors or the body's responses to tumors during tumorigenesis and progression, have been demonstrated to possess critical and encouraging value in screening and early diagnosis, prognosis prediction, recurrence detection, and therapeutic efficacy monitoring of cancers. Over the past decades, continuous progress has been made in exploring and discovering novel, sensitive, specific, and accurate tumor biomarkers, which has significantly promoted personalized medicine and improved the outcomes of cancer patients, especially advances in molecu

A Rare Presentation of Multiple Myeloma as a Second Primary Cancer Sequential to Non-Hodgkin Lymphoma: Case Report.

INTRODUCTION: The sequential occurrence of diffuse large B-cell lymphoma (DLBCL) a common type of non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM) is exceedingly rare, presenting a significant challenge in both diagnosis and treatment. CASE PRESENTATION: The case report discusses a 60-year-old male patient with a history of DLBCL which was diagnosed following symptoms of fever, weight loss and night sweats. He was treated with RVP (rituximab 375 mg/m2, vincristine 1.4 mg/m2, prednisolone 60 mg/m2) and R-CHOP regimen (rituximab 375 mg/m2, cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2,

Emerging trends in the coexistence of primary lung Cancer and hematologic malignancy: a comprehensive analysis of clinicopathological features and genetic abnormalities.

BackgroundThe incidence of multiple primary cancers (MPC), especially involving primary lung cancer (PLC) and primary hematologic malignancies (PHM), is rising. This study aims to analyze clinicopathological features, gene abnormalities, and prognostic outcomes in individuals diagnosed with PLC-PHM MPC.MethodsA retrospective analysis included 89 patients diagnosed with PLC-PHM MPC at the Respiratory or Hematology Departments of Ruijin Hospital from 2003 to 2022 (a total of 842,047 people). Next-generation sequencing (NGS) assessed lung cancer specimens, while Polymerase Chain Reaction (PCR) an

Role of microRNAs in hematological malignancies research: A bibliometric analysis.

ObjectivesMicroRNAs (miRNAs) are pivotal regulators of cancer biology, including hematological malignancies. Their roles include tumor suppression, oncogenic activities, modulation of immune responses, and treatment resistance. This study aimed to provide a quantitative analysis of research trends, thematic evolution, and key contributions to the field of miRNAs and hematological malignancies.MethodsUsing BIBLIO-Checklist and advanced visualization tools (VOSviewer and bibliometrix), data from key databases were analyzed for publication trends, author co-citations, thematic clusters, and emerg

Совпадение в полном тексте источника
… Data retrieval Searches were undertaken on Scopus using following formula: [TITLE-ABS-KEY((“microRNA” OR “miRNA”) AND (“hematological disorders” OR “hematologic neoplasms” OR “acute myeloid leukemia” OR “chronic lymphocytic leukemia” OR “Hodgkin lymphoma” OR “Non-Hodgkin lymphoma” OR “multiple myeloma …

An Italian cartography of VEXAS-related thrombosis.

Thrombotic events (TEs) occur in up to 40% of patients with vacuoles, E1 enzyme, X-linked, autoinflammatory, and somatic (VEXAS) syndrome, but data on its clinical-genomics features and anticoagulation strategies are limited. To gain more insight into this, we conducted a two-step study evaluating the prevalence and outcome of TE in VEXAS. First, among 1086 patients followed for TEs, 198 were men aged >40 years with unprovoked thrombosis and no known thrombophilia; 21 also had at least one VEXAS-compatible feature and underwent UBA1 exon 3 testing. No UBA1 mutation was detected in these 21 pat

Genome agnostic, multi-level non-oncogene addiction-based systems pharmacology for rescuing metastatic relapsed/refractory neoplasias.

Rescue therapies for relapsed/refractory (r/r) metastatic neoplasias present significant unmet needs. Tumor tissue editing regimen for 13 r/r tumor types, carcinomas, sarcomas and hematologic neoplasias, included in 15 phase I/II trials, nuclear/cytokine receptor agonists, pioglitazone, plus/minus dexamethasone or all-trans retinoic acid or interferon-α to counterbalance tumor tissue homeostasis and reprogramming of cancer hallmarks, stress response inhibitors, COX-2 inhibitor, everolimus, lenalidomide, or clarithromycin, and a stress response inducer, low-dose metronomic chemotherapy with tre

Prevalence of Depression in Patients with Hematologic Diseases in Marrakesh, Morocco: A Single Center Experience.

Depression in patients with cancer negatively influences their physical symptoms, treatment success, coping, and quality of life and is associated with increased mortality. The reported prevalence of emotional distress in patients followed in hematology varies widely across studies. This study investigated the prevalence of depression and explored the possible associated factors in patients followed in a hematological department.Methodsin this descriptive cross-sectional study of patients followed in the hematology department of the University Hospital Mohammed VI of Marrakesh between August 2

Risk of second primary cancer among breast cancer patients: A systematic review and meta-analysis.

ObjectivesThe aim of this study was to estimate the extra risk of second primary cancer among breast cancer patients.Methods and materialsThis is a systematic review. A comprehensive search of literature was performed in PubMed, Web of Science, Cochrane library, and Scopus. The search included all published studies up to October 2022. This systematic review included studies published in the English language that reported the risk of second primary non-breast cancer [i.e., standardized incidence ratio (SIR)] among breast cancer patients older than 15 years. After evaluating the methodological q

Периодическая эпистоксика как редкая презентация экстрамеуллярной мультимиеломы.

Множественная миелома, отличающаяся распространением клональных плазменных клеток за пределами костного мозга, связана с неблагоприятным прогнозом, особенно в тех случаях, когда она сопровождается цитогенетическими отклонениями высокого риска. С китайской стороны редко случается, и она может быть сопряжена с периодическими эпистазами или односторонними носовыми обструкциями, что создает диагностическое дублирование с подстрекательскими, сосудистыми, лимфоидными и эпителиальными синузами. Мы сообщаем о 54-летнем мужчине с восьмимесячной историей прогрессивной правосторонней носовой обструкции и

Поздние осложнения после Европейского агентства медицины - усовершенствованный антигенный приемник T-Cell терапия в гематологических злокачествах: обзор скопирования.

Лечение химерного антигенного рецептора T-клетка (CAR-T) значительно улучшило результаты лечения пациентов с гематологическими заболеваниями, связанными с B-клетками. Хотя острые и ранние токсичные вещества хорошо известны, поздние осложнения (ОС) по-прежнему плохо понимаются. Цель этого аналитического обзора заключалась в выявлении и картировании имеющихся данных о ЛК у взрослых пациентов с гематологическими заболеваниями, обработанных продуктами ЦАР-Т, утвержденными Европейским агентством по медицине (ЕМА). Были проведены обыски в Пубмеде, на веб-сайте науки и в Кокранской библиотеке на пред

Evaluation of psychosocial distress in patients treated in a community-based oncology group practice in Germany.

BackgroundSystematic evaluation of psychosocial distress in oncology outpatients is an important issue. We assessed feasibility and benefit of standardized routine screening using the Distress Thermometer (DT) and Problem List (PL) in all patients of our community-based hematooncology group practice.Patients and methodsOne thousand four hundred forty-six patients were screened between July 2008 and September 2008. Five hundred randomly selected patients were sent a feedback form.ResultsThe average distress level was 4.7, with 37% indicating a distress level >5. Patients with nonmalignant disea

Clinical outcome of therapy-related acute myeloid leukemia patients. Real-life experience in a University Hospital and a Cancer Center in France.

Backgroundt-AML occurs after a primary malignancy treatment and retains a poor prognosis.AimsTo determine the impact of primary malignancies, therapeutic strategies, and prognostic factors on clinical outcomes of t-AML.ResultsA total of 112 adult patients were included in this study. Fifty-Five patients received intensive chemotherapy (IC), 33 non-IC, and 24 best supportive care. At t-AML diagnosis, 42% and 44% of patients presented an unfavorable karyotype and unfavorable 2010 ELN risk profile, respectively. Among treated patients (n = 88), 43 (49%) achieved complete remission: four out of 33

Risk Factors and Prevention of Cancer and CVDs: A Chicken and Egg Situation.

Cardiovascular diseases and cancer are the two primary causes of mortality worldwide. Although traditionally regarded as distinct pathologies, they share numerous pathophysiological mechanisms and risk factors, including chronic inflammation, insulin resistance, obesity, and metabolic dysregulation. Notably, several cancers have been identified as closely linked to cardiovascular diseases, including lung, breast, prostate, and colorectal cancers, as well as hematological malignancies, such as leukemia and lymphoma. Additionally, renal and pancreatic cancers exhibit a significant association wi

Обработка возвращенных/отсутствующих t()11;14Множественный синдром миеломы и инфракрасного синдрома высокой степени риска с венецоклаксом.

Пациенты с множественной миеломой (ММ) имеют свойственный им риск вторичных миелоидных заболеваний. В тех случаях, когда эти гематоологические магнации сопутствуют друг другу, необходимы новаторские подходы к лечению. Венецоклакс (VEN), ингибитор BCL2, используется в сочетании с Azacitidine в острой миэлоидной лейкемии, в пробной среде при миэлодипластическом синдроме повышенного риска (MDS) и в t()11; 14) MM в спасательной системе. В этой связи мы представим доклад о параллельном рассмотрении дел, связанных с МОБ и t, сопряженных с высоким риском (см.11; 14) MM у пациента, использующего венер

Pharmacoutilization of epoetins in naïve patients with hematological malignancies in an unselected Italian population under clinical practice setting: a comparative analysis between originator and biosimilars.

AimThe purpose of this study was to assess the prescription of epoetins and consumption of health care resources (in terms of drug treatments) in naïve patients with hematological malignancies in a real-world setting; in particular, we compared the results between reference product and biosimilar products.MethodsAn observational retrospective study based on administrative and laboratory databases of three local health units was conducted. All adults diagnosed with hematological malignancies and who had received at least one epoetin (either reference product or biosimilars) prescription for the

Case Report: Endothelial-targeted bridging therapy for a TTP-like phenotype in fulminant iMCD-TAFRO.

BACKGROUND: iMCD-TAFRO (the TAFRO clinical subtype of idiopathic multicentric Castleman disease (iMCD)) is characterized by thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly. Diagnosis is challenging due to its rarity, non-specific early presentation, and overlap with sepsis, lymphoma, and thrombotic microangiopathy (TMA). Endothelial injury is increasingly recognized as a central driver of its severe complications. CASE PRESENTATION: A previously healthy 20-year-old woman presented with rapid progression of fever, anasarca, jaundice, and respiratory failure. Laboratory